These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28343973)

  • 1. New NICE criteria for drug access.
    Fricker J
    Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
    [No Abstract]   [Full Text] [Related]  

  • 2. Pfizer to make palbociclib temporarily free on NHS.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
    [No Abstract]   [Full Text] [Related]  

  • 3. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer Drugs Fund of minimal benefit.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
    [No Abstract]   [Full Text] [Related]  

  • 5. Health policy: Putting a price on cancer.
    Sullivan R; Aggarwal A
    Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
    [No Abstract]   [Full Text] [Related]  

  • 6. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 7. UK Government urged to recognise post-COVID-19 cancer backlog.
    Wilkinson E
    Lancet Oncol; 2021 Jul; 22(7):910. PubMed ID: 34090554
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
    Mancini R; McBride A; Kruczynski M
    Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
    [No Abstract]   [Full Text] [Related]  

  • 9. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 10. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 11. New Cancer Drugs Fund is flawed without NICE reform, says Roche.
    Hawkes N
    BMJ; 2016 Jul; 354():i4216. PubMed ID: 27473207
    [No Abstract]   [Full Text] [Related]  

  • 12. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 13. [The electoral programs of political parties and Health: a handbook to guide].
    Quintaliani G; Rollino C; Sepe V; Di Iorio B
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083524
    [No Abstract]   [Full Text] [Related]  

  • 14. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit".
    Cohen D
    BMJ; 2017 Apr; 357():j2097. PubMed ID: 28455308
    [No Abstract]   [Full Text] [Related]  

  • 15. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies.
    Value Health; 2008; 11(1):129-30. PubMed ID: 18179656
    [No Abstract]   [Full Text] [Related]  

  • 17. How to Put a Value on the Priceless.
    Read C
    Health Serv J; 2017 Mar; 127(6509):10-1. PubMed ID: 30088901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intergenerational report misses the point on health spending.
    Duckett S
    Australas J Ageing; 2015 Dec; 34(4):214-6. PubMed ID: 26643227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.